Comment
The safety features of computing systems currently in use in about three quarters of UK general practices have clinically important deficiencies. All may fail to warn in a situation when a warning is expected, thus potentially creating a health hazard to patients.
One solution to this problem is to have more explicit regulations about the situations in which suppliers should implement specific alerts. Because information technology, pharmacology, and medicine are dynamic fields, suppliers of systems and drug databases would need to have regular dialogue with end users about ways of further improving the safety features of these important aides to clinical management. Our discussions with manufacturers indicate that many of the problems uncovered could be resolved, and this work is now being taken forward by the National Patient Safety Agency.
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Funding: National Patient Safety Agency. The prescribing process is complex, and opportunities for error abound. Patients may be given drugs they are allergic to, or which are contraindicated or have already been prescribed under another name; one drug may interact with another; the dosage, or duration, or formulation, or route may be wrong: in short, anything that can go wrong in prescribing will go wrong.
Computers can help. They reduce medication error rates by as much as 60% simply by ensuring that prescriptions are legible, complete, and in a standard format.
2 That is encouraging, but patients still die from the remaining errors. The NHS Information Authority requires that systems used in general practice "shall cross check prescriptions for known sensitivities, interactions and active ingredient duplications in the patient record. An appropriate warning to the prescriber shall be given." 3 But GP prescribers put their trust in these systems at their patients' peril. Fernando and colleagues tested four computer prescribing systems. 4 One failed to meet the NHS requirements; others failed to warn of potentially serious prescribing errors, especially where drugs were contraindicated. Contraindications account for about 4% of adverse drug events in general practice. The systems could be improved. They might list every contraindication to a drug whenever it was prescribed. That change would trap more errors but risk overwhelming the user with alerts: primary care physicians ignore alerts from nagging computers.
5
Relevance is the key. Prescribers need not be reminded constantly that etoricoxib is contraindicated in inflammatory bowel disease, that nalidixic acid should be withheld from patients with epilepsy or porphyria, or that hyoscine-N-butylbromide should be avoided in patients with myasthenia gravis. Yet timely and relevant warnings will prevent disaster. Hospital systems already exist that link patient history, laboratory results, and prescribing data and that present a hierarchy of warnings to inform, advise, and occasionally forbid the prescriber to continue. No human activity is error-free, and we have recognised belatedly that prescribing is complex and prone to error. We need to make it safer-which means increasing the chances that important errors will be avoided or caught by checks before they are translated into harm. We can and should ensure that prescribers-who now include nurses and pharmacists-learn to use medicines safely. Practical examinations in the core skills of therapeutics should help.
1 That will still leave patients vulnerable to prescribers' human failings. Computers can improve communications by generating a legible and complete prescription. But Fernando and colleagues show that several widely used systems fail to detect known prescribing errors. Those who walk the therapeutic tightrope in general practice will want the assurance of a safety net that will catch important errors before they harm patients, an assurance that current systems cannot provide. The title Side Effects of Drugs has stuck, through 14 editions of the encyclopedia and 26 volumes of the annual. But we now recognise that side effects of drugs, as well as toxic effects and hypersusceptibility effects, are particular forms of unwanted effects, and that the term "adverse effects" is preferable (Lancet 2000; 356:1255-60) . A toxic effect is one that occurs at high doses, by exaggeration of the desired therapeutic effect. For example, a cardiac arrhythmia due to digoxin is a toxic effect-it occurs by the same mechanism as the therapeutic effect.
On the other hand, an unwanted side effect (or, better, a collateral effect; see BMJ 2003; 327:1222-5) occurs at the usual therapeutic dose, usually in some tissue other than the site of the therapeutic effect, and sometimes via some non-therapeutic mechanism. For example, the anticholinergic effect of a tricyclic antidepressant is a side effect, since this action is not responsible for the therapeutic effect. Impaired colour vision caused by sildenafil inhibiting phosphodiesterase type V in the eye is a side effect, since the phosphodiesterase you want to inhibit is in the corpora cavernosa.
Side effects may also be beneficial rather than harmful. For example, treating hypertension with a blocker may, by blockade, also relieve angina, a beneficial side effect. Alternatively, a depressed patient with irritable bowel syndrome may incidentally benefit from the anticholinergic side effect of a tricyclic antidepressant as well as from its antidepressant action.
Finally, hypersusceptibility effects typically occur at low doses and are often immunological in mechanism. The term "adverse effect" encompasses all these types of unwanted effects and makes no assumptions about mechanism or relation to dose. Now, talking about adverse effects looks at things from the point of view of the drug. But it has instead become common to talk about "adverse reactions," looking at them from the point of view of the patient, and specifically about "adverse drug reactions" (ADRs). However, the term "drug" excludes contaminants (such as in herbal medicines) or supposedly inactive excipients in a formulation. And so, recognising that medicinal products contain ingredients other than active principles, I propose that we should talk about adverse reactions to medicines or medicaments, ARMs rather than ADRs. And don't we all want a farewell to ARMs?
And since Meyler's book is soon to appear in electronic format, with the provisional title Meyler's International Encyclopedia of Adverse Drug Reactions, I like to regard its database as Highlighting Adverse Reactions to Medicines. And where's the HARM in that?
Jeff Aronson clinical pharmacologist, Oxford
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